About 30% of CML patients in CP with resistance to first or second-generation of tyrosine kinase inhibitors (TKIs) harbor mutations in the BCR::ABL1 kinase domain. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.